Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia - A dose-response trial

Cerebellum

Volumn 10, Issue 4, 2011, Pages 763-769

  Nachbauer, Wolfgang ^a   Hering, Sascha ^a   Seifert, Markus ^a   Steinkellner, Hannes ^b   Sturm, Brigitte ^b   Scheiber Mojdehkar, Barbara ^b   Reindl, Markus ^a   Strasak, Alexander ^a   Poewe, Werner ^a   Weiss, Guenter ^a   Boesch, Sylvia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Erythropoietin iron; Friedreich ataxia; Mitochondria

Indexed keywords

ADENOSINE TRIPHOSPHATE; FERRITIN; FRATAXIN; HEMOGLOBIN; IDEBENONE; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UBIDECARENONE;

ADULT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; FRIEDREICH ATAXIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; LOW DRUG DOSE; MALE; MITOCHONDRION; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPREGULATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; MITOCHONDRIA; PILOT PROJECTS; RECOMBINANT PROTEINS;

EID: 84855941558     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-011-0287-9     Document Type: Review

References (29)

1. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intra-familial clustering of clinical features. Brain. 1981;104:589-620. (Pubitemid 12202197)
2. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med. 2004;82:510-29. (Pubitemid 39149861)
3. Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999;87:168-74. (Pubitemid 29530423)
4. Milbrandt TA, Kunes JR, Karol LA. Friedreich's ataxia and scoliosis: the experience at two institutions. J Pediatr Orthop. 2008;28:234-8. (Pubitemid 351498933)
5. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423-7. (Pubitemid 26089479)
6. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, Monticelli A, et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry. 2004;75:1061-3. (Pubitemid 38869629)
7. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 2008;24:398-407.
8. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17:215-7.
9. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26:1269-74. (Pubitemid 43237059)
10. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2009;6:108-27.
11. Sturm B, Stupphann D, Kaun C, Boesch S, Schranzhofer M, Wojta J, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005;35:711-7. (Pubitemid 41640907)
12. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007;62:521-4. (Pubitemid 350308777)
13. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord. 2008;23:1940-4.
14. Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord. 2009;24:1779-84.
15. Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717-20. (Pubitemid 43964628)
16. Steinkellner H, Scheiber-Mojdehkar B, Goldenberg H, Sturm B. A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Anal Chim Acta. 2010;659:129-32.
17. Cox C, Camus P, Duvivier J. An enzymatic cycling procedure for NAD+ using an irreversible reaction with NAD+-peroxidase. Anal Biochem. 1982;119:185-93.
18. Oexle H, Gnaiger E, Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta. 1999;1413:99-107. (Pubitemid 29507549)
19. Erslev AJ. Erythropoietin titers in health and disease. Semin Hematol. 1991;28:2-7. discussion 7-8.
20. Heatherington AC. Clinical pharmacokinetic properties of rhuEPO: a review. In: Molineux G, Foot MA, Elliott SG, editors. Erythropoietins and erythropoiesis molecular, cellular, preclinical, and clinical biology. Boston: Birkhäuser Basel; 2003. p. 87-112.
21. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44:991-1002. (Pubitemid 39096814)
22. Sacca F, Piro R, De Michele G, Acquaviva F, Antenora A, Carlomagno G, et al. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov Disord. 2010;26:739-42.
23. Means Jr RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003;2:116-21.
24. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
25. Busfield SJ, Tilbrook PA, Callus BA, Spadaccini A, Kuhn L, Klinken SP. Complex regulation of transferrin receptors during erythropoietin-induced differentiation of J2E erythroid cells - elevated transcription and mRNA stabilisation produce only a modest rise in protein content. Eur J Biochem. 1997;249:77-84. (Pubitemid 27432598)
26. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007;78:183-205.
27. Weiss G, Houston T, Kastner S, Johrer K, Grunewald K, Brock JH. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood. 1997;89:680-7. (Pubitemid 27051705)
28. Campanella A, Rovelli E, Santambrogio P, Cozzi A, Taroni F, Levi S. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet. 2009;18:1-11.
29. Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Suryo Rahmanto Y. The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. J Mol Med. 2009;88:323-9.